ABBA Therapeutics AG, a Swiss biotechnology company developing innovative immuno-oncology therapies, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) have entered into a worldwide license agreement. Under the license, ABBA Therapeutics AG will be able to use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies.

VISCHER advised ABBA Therapeutics AG in the negotiations. The VISCHER team includes partner Christian Wyss and Luzius Zumstein.